naltrexone has been researched along with Liver Neoplasms in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chia, BK; Tey, HL | 1 |
Harlos, MS; Hohl, CM; Wong, JK | 1 |
Berkson, AJ; Berkson, BM; Rubin, DM | 2 |
4 other study(ies) available for naltrexone and Liver Neoplasms
Article | Year |
---|---|
Metastatic hepatocellular carcinoma with paraneoplastic itch: effective treatment with naltrexone.
Topics: Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasm Metastasis; Paraneoplastic Syndromes; Pruritus; Treatment Outcome | 2014 |
Methylnaltrexone to Palliate Pruritus in Terminal Hepatic Disease.
Topics: Aged; Carcinoma, Hepatocellular; Fatal Outcome; Female; Gallbladder Neoplasms; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pain Measurement; Pruritus; Quaternary Ammonium Compounds; Terminal Care | 2015 |
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatal Outcome; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Naltrexone; Pancreatic Neoplasms; Thioctic Acid | 2009 |
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Naltrexone; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Treatment Outcome | 2006 |